Australia's largest stock trading and investment forum Australia's #1 stock forum

RAP

Click for more information

0.00%

20.5¢ resapp health limited

Ann: Positive Results for Australian Prospective Paediatric Study, page-108

First 108 Last

Share
Profile

Follow
Area51

1,025 Posts.

105

03/09/18

14:26

Post #: 35377193
Share

Originally posted by Tech goose ↑

The outstanding results delivered by the Breathe Easy prospective study are consistent with our expectations, and for diseases such as pneumonia and asthma have even exceeded our expectations. This formal confirmation of ResApp’s algorithms’ robust performance will allow us to provide key diagnostic products in an array of clinical settings, especially in telehealth - one of the fastest growing segments in healthcare - where up to 50% of consultations are respiratory related”, said Tony Keating, CEO and Managing Director of ResApp. “We now have a solid dataset to underpin our forthcoming CE mark and TGA submissions which will propel the commercialisation of our products in Europe, Australia and the rest of the world outside the US. The successful completion of Breathe Easy also gives us additional data, experience and confidence as we finalise our US SMARTCOUGH-C-2 study.”

Are we reading the same thing???

Expand

Yes we are - do you understand what you are reading thats the question?

RAP Price at posting: 25.5¢ Sentiment: Sell Disclosure: Not Held
Upvote

0 Great analysis

Reply

Top Stories

Bitcoin investors need to know the risks

NIM

Nimy to raise $1.21M to explore 'newsy' WA targets

MDI

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

AII

Almonty locks in govt agreement for tungsten oxide plant in South Korea

I88

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

There are more pages in this discussion • 262 more messages in this thread...

First 108 Last

Add RAP (ASX) to my watchlist